Amplia Therapeutics Limited's (ASX:ATX) Dr John Lambert speaks to Proactive's Andrew Scott following the news they've begun dosing the first volunteers in its Phase 1 clinical trial of AMP945. The molecule's being developed for difficult-to-treat cancers and fibrotic diseases. Amplia expects to complete dosing in the trial during the first half of next year, which should allow reporting of top-line results around the middle of 2021.
Amplia Therapeutics CEO says dosing in its phase one trial is 'enormous' milestone
Quick facts: Amplia Therapeutics Ltd
Price: 0.2 AUD
Market Cap: $21.49 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Amplia Therapeutics Ltd named herein, including the promotion by the Company of Amplia Therapeutics Ltd in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE